Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2020
Cited by 837 works. doi:10.1016/s1470-2045(20)30453-8
Authors
- Mariano Provencio
- Ernest Nadal
- Amelia Insa
- M.R. García-Campelo
- Joaquín Casal‐Rubio
- Manuel Dómine
- Margarita Majem
- Delvys Rodríguez‐Abreu
- Alex Martínez‐Martí
- Javier de Castro
- Manuel Cobo
- Guillermo López-Vivanco
- E. del Barco
- Reyes Bernabé
- Núria Viñolas
- Isidoro Barneto Aranda
- Santiago Viteri
- Eva Pereira
- Ana Royuela
- Marta Casarrubios
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- AJCC Cancer Staging Manual
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Cancer statistics, 2020
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
- Regulatory T Cells and Immune Tolerance
- AJCC Cancer Staging Manual
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up